Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

被引：13

作者：

Cohen, Ezra E. W.

Nabell, Lisle

Wong, Deborah J. L.

Day, Terry A.

Daniels, Gregory A.

Milhem, Mohammed M.

Deva, Sanjeev

Jameson, Michael B.

Guntinas-Lichius, Orlando

Almubarak, Mohammed

Strother, Robert Matthew

Whitman, Eric D.

Chisamore, Michael Jon

Obiozor, Cynthia Chinedu

Bagulho, Teresa

Candia, Albert

Gamelin, Erick

Janssen, Robert

Algazi, Alain Patrick

机构：

[1] Univ Calif San Diego, La Jolla, CA 92093 USA

[2] Univ Alabama Birmingham, Birmingham, AL USA

[3] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA

[4] Med Univ South Carolina, Charleston, SC 29425 USA

[5] Univ Iowa, Iowa City, IA USA

[6] Auckland City Hosp, Auckland, New Zealand

[7] Waikato Hosp, Reg Canc Ctr, Hamilton, New Zealand

[8] Univ Hosp Jena, Head & Neck Surg, Jena, Germany

[9] West Virginia Univ, Morgantown, WV 26506 USA

[10] Christchurch Hosp, Canterbury Dist Hlth Board, Christchurch, New Zealand

[11] Atlantic Hlth Syst Canc Care, Morristown, NJ USA

[12] Merck & Co Inc, Rahway, NJ 07065 USA

[13] Dynavax Technol Corp, Berkeley, CA USA

[14] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.6039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6039

引用

页数：2

共 50 条

[31] NEMVALEUKIN ALFA, A NOVEL ENGINEERED IL-2 CYTOKINE, IN COMBINATION WITH THE ANTI-PD-1 ANTIBODY PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (ION-01 STUDY)
Gastman, Brian
Cheever, Mac
Fling, Steven
Perez, Cesar
Patel, Manish
Geiger, Jessica
Li, Zujun
Posner, Marshall
Steuer, Conor
D'Amico, Leonard
Kask, Angela Shaulov
Du, Yangchun
Matthies, Derek
Huh, Sung Jin
Wang, Yan
Graham, Julie
Chow, Laura
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A462 - A462
[32] Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012
Chow, L.
Mehra, R.
Haddad, R.
Gupta, S.
Weiss, J.
Berger, R.
Burtness, B.
Tahara, M.
Keam, B.
Le, D.
Cheng, J.
Heath, K.
Pathiraja, K.
Seiwert, T.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S579 - S579
[33] Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy
Ribas, A.
Mehmi, I.
Medina, T.
Lao, C.
Kummar, S.
Amin, A.
Deva, S.
Salama, A. K.
Tueting, T.
Milhem, M.
Hoimes, C. J.
Daniels, G.
Shaheen, M.
Jang, S.
Barve, M.
Powell, A.
Chandra, S.
Schmidt, E. V.
Janssen, R.
Long, G. V.
ANNALS OF ONCOLOGY, 2018, 29
[34] CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001+pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Wong, Deborah J. L.
Panwar, Aru
Rosenberg, Ari
Karivedu, Vidhya
Laux, Douglas Earl
Zandberg, Dan Paul
Bobilev, Dmitri
Zhao, Luping
Wooldridge, James
Krieg, Art M.
Cohen, Ezra E. W.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] Letter to the editor, "Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell carcinoma: A multicenter, open-label, single-arm, phase 1b study."
Jeyaraj, Gnanaprakash
ORAL ONCOLOGY, 2025, 163
[36] Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
Kim, E. S.
Kies, M. S.
Glisson, B. S.
Ginsberg, L. E.
Holsinger, F. C.
Burke, B. J.
Truong, M.
Tsao, A. S.
Hong, W. K.
Lippman, S. M.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 285S - 285S
[37] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
Taylor, Matthew H.
Rasco, Drew W.
Brose, Marcia S.
Vogelzang, Nicholas J.
Richey, Stephen Lane
Cohn, Allen Lee
Richards, Donald A.
Stepan, Daniel E.
Dutcus, Corina E.
Guo, Matthew
Shumaker, Robert Charles
Schmidt, Emmett V.
Wirth, Lori J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[38] Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.
Harrington, Kevin Joseph
Kong, Anthony
Mach, Nicolas
Chesney, Jason Alan
Castelo, Beatriz
Rischin, Danny
Cohen, Ezra E. W.
Radcliffe, Hoi-Shen
Gumuscu, Burak
Snyder, Wendy
Siu, Lillian L.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study
Flanagan, Kevin C.
Earls, Jon
Hiken, Jeffrey
Wellinghoff, Rachel L.
Ponder, Michelle M.
Mcleod, Howard L.
Westra, William H.
Vavinskaya, Vera
Sutton, Leisa
Deichaite, Ida
Macdonald, Orlan K.
Welaya, Karim
Wade, James, III
Azzi, Georges
Pippas, Andrew W.
Slim, Jennifer
Bank, Bruce
Sui, Xingwei
Kossman, Steven E.
Shenkenberg, Todd D.
Alexander, Warren L.
Price, Katharine A.
Ley, Jessica
Messina, David N.
Glasscock, Jarret, I
Colevas, A. Dimitrios
Cohen, Ezra E. W.
Adkins, Douglas
Duncavage, Eric J.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (11)
[40] Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck
Humphries, Audrey
Zhou, Connie J.
Welsh, Madeleine
Lem, Melinda
Kang, Hyunseok
Algazi, Alain P.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (02): : 321 - 327

← 1 2 3 4 5 →